Biotech News
Precision BioSciences Announces Positive DSMB Safety Review Supporting Additional PBGENE-DMD Dosing in Phase 1/2 FUNCTION-DMD Study
- First patient completed observation period following PBGENE-DMD treatment with no reported safety concerns - - Independent Data Safety Monitoring Board endorses proceeding with dosing additional patients - DURHAM, N.C. --(BUSINESS WIRE)--Nov. 5, 2026-- Precision BioSciences, Inc.
